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Quality of life of Bahraini women with breast
cancer: a cross sectional study
Ghufran Ahmed Jassim* and David L Whitford
Abstract
Background: Breast cancer can impact survivors in many aspects of their life. Scarce information is currently
available on the quality of life of cancer survivors in Bahrain. The objective of this study is to describe the quality of
life of Bahraini women with breast cancer and its association with their sociodemographic and clinical data.
Methods: This is a cross sectional study in which the European Organization for Research and Treatment of Cancer
Quality of Life Cancer Specific version translated into Arabic was administered to a random sample of 337 Bahraini
women with breast cancer. Relevant descriptive statistics were computed for all items. The equality of means across the
categories of each categorical independent variable was tested using parametric tests (ANOVA and independent t-test)
or non-parametric tests (Kruskal Wallis and Mann Whitney tests) of association where appropriate.
Results: Of the total sample, 239 consented to participation. The mean and median age of participants were 50.2 (SD
± 11.1) and 48.0 respectively. Participants had a mean score for global health of 63.9 (95% CI 61.21-66.66). Among
functional scales, social functioning scored the highest (Mean 77.5 [95% CI 73.65-81.38]) whereas emotional functioning
scored the lowest (63.4 [95% CI 59.12-67.71]). The most distressing symptom on the symptom scales was fatigability
(Mean 35.2 [95% CI 31.38-39.18]). Using the disease specific tool it was found that sexual functioning scored the lowest
(Mean 25.9 [95% CI 70.23-77.90]). On the symptom scale, upset due to hair loss scored the highest (Mean 46.3 [95% CI
37.82-54.84]). Significant mean differences were noted for many functional and symptom scales.
Conclusion: Bahraini breast cancer survivors reported favorable overall global quality of life. Factors associated with a
major reduction in all domains of quality of life included the presence of metastases, having had a mastectomy as
opposed to a lumpectomy and a shorter time elapsed since diagnosis. Poorest functioning was noted in the emotional
and sexual domains. The most bothersome symptoms were fatigability, upset due to hair loss and arm symptoms. This
study identifies the categories of women at risk of poorer quality of life after breast cancer and the issues that most
need to be addressed in this Middle East society.
Keywords: Breast cancer, Bahrain, Quality of life, Bahraini women, Middle East, EORTC
Background
Breast cancer is the most common cancer among
women worldwide. It accounts for 23% of all new can-
cers in women excluding cancers of the skin [1,2]. Breast
cancer is ranked as the most prevalent cancer among
women in the Arab world [1]. Advances in diagnostic
and treatment modalities have also resulted in increased
survival. Thus, coping with breast cancer as a chronic
disease is becoming a more common phenomenon.
In the Arab world, surgeons and oncologists dealing
with breast cancer tend to believe that it presents at an
earlier age with a more advanced stage at presentation
[3]. This impression is particularly evident in Bahrain
and other Gulf Cooperation Council [4] countries where
women aged less than 40 years make up a larger per-
centage of total breast cancer cases than do their coun-
terparts in Western countries [5,6]. In addition, Bahraini
women similar to other Arab women face cultural ta-
boos surrounding breast cancer. Some families fear that
their daughters will not be able to marry if a mother’s
diagnosis of breast cancer becomes known [7].
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The increased survival of breast cancer patients, the
younger age at diagnosis, and the unique set of cultural
norms and values all suggest that information on quality
of life (QoL) in this region may be specific and therefore
important to both health care providers and patients.
However, little information of this nature is available.
This study aims to describe the quality of life of Bahraini
women with breast cancer and to identify factors that
may facilitate improvements in health care for breast
cancer survivors in Bahrain.
Methods
Setting
Bahrain consists of an archipelago of islands located in
the Arabian Gulf. It has a population of 1,106,509, of
which 537,719(48.6%) are Bahrainis [8]. Bahrain has a
national health service with care being free at the point
of contact for Bahraini citizens. The main governmental
hospital is Salmaniya Medical Complex which hosts the
only oncology center in the country [4]. All diagnosed
breast cancer cases are referred to this center for further
adjuvant treatments.
Sampling and recruitment
This is a descriptive cross sectional study. Bahraini
women survivors of breast cancer diagnosed between 1st
January 1999 and 31st December 2008 were identified
from the Bahrain Cancer Registry. Non Bahraini women
were excluded on the basis that quality of life may differ
across different cultures and ethnic groupings. A sample
size of 337 subjects was calculated to give 85% power at
5% significance with an estimated non response rate of
20%. A simple random sample was drawn from the
Bahrain Cancer Registry using computer software. The
researcher conducted a 10-minute interview with the
participants after obtaining their consent in writing.
Study instruments
A structured questionnaire collecting sociodemographic
data, clinical information and quality of life data was
used. Time elapsed since diagnosis was defined as: early
after diagnosis (≤1 year since diagnosis), transitional
period (>1 and ≤5years since diagnosis) and long term
survivors (>5 to ≤10 years). Quality of life was assessed
using the European Organization for Research and
Treatment of Cancer QoL Cancer Specific Version
(EORTC QLQ-C30, v.3.0) translated into Arabic and val-
idated [9,10]. Items explored by the EORTC QLQ-30 in-
clude nine domains: global health, physical, role,
emotional, cognitive, social functioning, fatigue, nausea/
vomiting, pain, and financial impact. We also used the
QoL Breast Cancer Specific Version [9,10] translated
into Arabic. The EORTC QLQ-BR23 incorporates five
domains: therapy side effects, arm symptoms, breast
symptoms, body image, and sexual functioning.
Scores for these questions range between 0 and 100.
For scales evaluating global health and function, a higher
score represents higher level of functioning and health.
For scales evaluating symptoms, a higher score indicates
more problems and higher level of symptoms.
Ethical consideration
Ethical approval was obtained from the ethics committees
in the Royal College of Surgeons in Ireland-Medical Uni-
versity of Bahrain and the Ministry of Health in Bahrain.
Statistical analysis
A supplemental scoring manual is provided with the
questionnaire which was followed in the analysis [11].
The collected data were coded, entered and analyzed
using the statistical package SPSS version 15.0. Relevant
descriptive statistics were computed for all items. A
higher score represents a “better” level of functioning, or
a “worse” level of symptoms. The “Score” served as the
dependent variable in the study for the purpose of data
analyses. Sociodemographic data, cancer and treatment
information represented the independent variables.
The equality of means across the categories of each
categorical independent variable was tested using para-
metric tests (ANOVA and independent t-test). Non-
parametric tests (Kruskal Wallis and Mann Whitney
tests) were used if the statistical assumptions of using
the parametric tests were violated. Additional explor-
ation of the differences among means was determined
by post hoc analysis.
As recommended by an empirical population based
study [12], for the functional scales and the global qual-
ity of life, we defined subjects with problematic function-
ing as those who scored <33.3%, while subjects in good
condition scored ≥66.7%. For symptom scales, subjects
scoring < 33.3% were judged as having less severe symp-
toms, while those scoring ≥ 66.7% had more intense
symptoms.
Linear Regression Modeling was used to build a pre-
dictive model to assess the significance of predictors and
to compute the coefficient of determination. Global
health, physical, emotional, cognitive and social func-
tioning scores served as the dependent variables. All
independent variables (age, duration since diagnosis,
marital status, educational level, employment status, in-
come, menopausal status, co-morbidities, pathological
staging, history of metastases, lumpectomy, mastectomy,
lymph node dissection , radiotherapy, hormonal therapy
and chemotherapy) were categorized into two (yes and
No) categories and served as predictors for the models.
R squared was computed. A P-value <0.05 was consid-
ered statistically significant.
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Results
Details of 337 Bahraini women with breast cancer were
taken from the Bahrain Cancer Registry. Among the
sample taken from the registry 18 had died and 66 were
inaccessible. Seven were ineligible due to language bar-
rier, deafness or wrong diagnosis, and seven refused to
participate (reasons for not participating were lack of
time, extreme anxiety, unwillingness to share their ex-
perience or not wanting to be reminded of their experi-
ence with cancer). Two hundred and thirty nine women
consented to participate and were interviewed by the
researcher (recruitment rate 71%).
Characteristics of the study sample
The characteristics of the sample are presented in
Table 1. The mean and median ages of participants were
50.2 (SD ± 11.1) and 48.0 years respectively. Mean time
elapsed since diagnosis was 4.22 (SD ± 2.69) years.
Profile of quality of life scale scores
Participants had a mean score for global health of 63.9
(95% CI 61.2-66.6). Among functional scales, social
functioning scored the highest (77.5 [95% CI 73.65-
81.38]) whereas emotional functioning scored the lowest
(63.4 [95% CI 59.12-67.71]).
The most distressing symptom on the symptom scales
was fatigability (Mean 35.2 [95% CI 31.38-39.18])
followed by sleep disturbance and pain (Table 2). Using
the disease specific tool it was found that sexual func-
tioning scored the lowest (Mean 25.9 [95% CI 70.23-
77.90]) indicating poor functioning whereas body image
scored the highest (Mean 75.64 [95% CI 71.79-79.48]).
On the symptom scale, upset due to hair loss scored the
highest (Mean 46.3 [95% CI 37.82-54.84]) indicating
worse functioning followed by arm symptoms (Mean
36.58 [95% CI 32.50-40.65]).
Factors associated with QoL scale scores
Global health and Functional scale in QLO-C30
There were significant differences in the global health
means across categories of marital status (P =0.041),
menopausal status (P =0.016), history of metastases
(P = 0.016), monthly income (P =0.036) and type of
surgery (P =0.026 and 0.017 for mastectomy and lump-
ectomy respectively). Post hoc analysis results revealed
that subjects who were not married, premenopausal,
with no history of metastases, have high income and
who were treated by lumpectomy tended to have better
global health related quality of life (Table 3).
Differences in the physical functioning means were ob-
served across categories of educational level (P =0.009),
history of metastases (P =0.001) and history of lumpec-
tomy (P =0.033). Post hoc analysis showed that educated
subjects who finished high school and had conservative
breast surgery (lumpectomy) had better functioning on
the physical scale.
Symptom scales in QLQ-C30
With the exception of financial impact, there were
significant differences in all symptom scales across
Table 1 Characteristics of the study population N = 239
Characteristic No. %
Age n = 239
≤50 year 137 57.3
>50 years 102 42.7
Time since diagnosis n = 239
Early diagnosed 35 14.6
Transitional period 128 53.6
Long term survivors 76 31.8
Educational level n = 236
Illiterate 60 25.4
Primary 30 12.7
Intermediate 23 9.7
High school/diploma 81 34.4
College graduate 42 17.8
Employment n = 236
Yes 50 21.2
No 146 61.9
Retired 40 16.9
Monthly income n = 235<500 132 56.2
500–1000 57 24.3
> 1000 46 19.5
Menopausal status n = 236
Premenopause 110 46.6
Perimenopause 36 15.3
Postmenopause 90 38.1
Pathological staging n = 134
Stage 0 and I 40 29.9
Stage II 60 44.8
Stage III and IV 34 25.3
Distant metastasis n = 236
Yes 17 7.2
No 219 92.8
Treatment modality n = 236
Lumpectomy 121 51.3
Mastectomy 118 50.0
Lymph node dissection 200 85.1
Chemotherapy 190 80.5
Radiotherapy 198 83.9
Hormonal therapy 164 69.8
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categories of metastasis. Post hoc analysis showed that
women with metastases experienced worse symptoms.
Differences in pain means were seen among age (P =
0.003), menopause (P = 0.003) and metastases categories
(P = 0.001). Post hoc analysis revealed that younger, pre-
menopausal women and those with a history of metasta-
ses experienced more pain.
Functional and symptom scales in QLQ-BR 23
Differences in means of body image were significant
among categories of educational level (P = 0.029), and
mastectomy (P = 0.022). Post hoc analysis showed that
women who had undergone mastectomy and were
highly educated tended to have poorer body image
(Table 4). Better sexual functioning was observed for
married women (P < 0.001), high income (P < 0.001),
long term survivors (P = 0.027).
More intense upset by hair loss was noted among
women who were recently diagnosed (P = 0.035); di-
vorced as opposed to single women (P = 0.020) and
those who had intermediate education (P = 0.021).
Women who had metastases complained of more
severe systemic side effects (P = 0.013), breast (P = 0.008)
and arm symptoms (P = 0.033).
Women who were recently diagnosed were more wor-
ried about their future (P = 0.037), and complained of
more breast symptoms (P = 0.044) and were more upset
by the loss in their hair (P = 0.035).
Table 2 Mean score of all items in QLQ-C30 and QLQ-BR23 (N = 239)
Variables N No. of items Mean (SD) 95% CI N (%) scoring <33.3)a N (%) scoring ≥66.7)a
QLQ-C30
Global health status/QoL 238 2 63.93(21.34) 61.21-66.66 13(5.4) 92(38.5)
Functional scalesb
Physical functioning 239 5 74.92(21.69) 72.15-77.68 9(3.8) 154(64.4)
Role functioning 237 2 68.84(35.96) 64.24-73.44 33(13.8) 132(55.2)
Emotional functioning 236 4 63.41(33.46) 59.12-67.71 52(21.8) 118(49.4)
Cognitive functioning 238 2 73.38(29.87) 69.57-77.20 24(10.0) 140(58.6)
Social functioning 238 2 77.52(30.27) 73.65-81.38 21(8.8) 152(63.6)
Symptom scalesc
Fatigue 239 3 35.28(30.62) 31.38-39.18 117(49.0) 39(16.3)
Nausea and vomiting 238 2 10.29(30.77) 6.36-14.22 208(87.0) 9(3.8)
Pain 238 2 29.97(31.23) 25.98-33.96 135(56.5) 31(13.0)
Dyspnoea 239 1 20.22(30.32) 16.35-24.08 149(62.3) 15(6.3)
Sleep disturbance 239 1 30.12(39.29) 25.11-35.13 136(56.9) 42(17.6)
Appetite loss 239 1 13.38(27.62) 9.86-16.90 185(77.4) 11(4.6)
Constipation 239 1 17.99(30.66) 14.08-21.89 163(68.2) 18(7.5)
Diarrhea 239 1 6.83(18.95) 4.41-9.24 205(85.8) 4(1.7)
Financial impact 239 1 34.58(42.26) 29.20-39.97 130(54.4) 57(23.8)
QLQ-BR23
Functional scalesb
Body image 234 4 75.64(29.86) 71.79-79.48 24(10.0) 160(66.9)
Sexual functioning 234 2 25.92(29.77) 70.23-77.90 10(4.2) 129(54.0)
Sexual enjoyment 116 1 48.56(32.12) 45.52-57.34 16(6.7) 23(9.6)
Future perspective 236 1 61.29(39.37) 56.25-66.34 43(18.0) 105(43.9)
Symptom scalesc
Systemic side effect 236 7 19.27(17.76) 16.98-21.55 187(78.2) 4(1.7)
Breast symptoms 236 4 13.66(18.06) 11.34-15.98 195(81.6) 4(1.7)
Arm symptoms 236 3 36.58(31.76) 32.50-40.65 113(47.3) 34(14.2)
Upset by hair loss 100 1 46.33(42.87) 37.82-54.84 38(15.9) 32(13.4)
aFor functional scales, subjects scoring < 33.3% have problems; those scoring ≥ 66.7% have good functioning. For symptom scales/symptoms, subjects scoring
< 33.3% have good functioning; those scoring = 66.7% have problems.
bFor functional scales, higher scores indicate better functioning.
cFor symptom scales, higher scores indicate worse functioning.
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Table 3 Global health and functional scales in QLQ-C30 by independent variables (N = 239)a
Characteristic Global
health
/QoL
Mean
(SD)
Functional scales in QLQ-C30b
Physical functioning
Mean(SD)
Role functioning
Mean (SD)
Emotional functioning
Mean (SD)
Cognitive functioning
Mean (SD)
Social functioning
Mean (SD)
Age
≤50 year 67.7
(20.04)
77.37(20.47) 69.97(37.06) 60.30(33.32) 70.31(30.42) 76.03(32.89)
>50 years 58.90
(22.07)
71.63(22.91) 67.32(34.55) 67.57(33.37) 77.55(28.71) 79.53(26.33)
P-value 0.147 0.271 0.176 0.710 0.412 0.005
Time since
diagnosis
Early diagnosed 61.66
(27.20)
74.09(24.02) 58.82(40.04) 55.00(38.57) 70.95(32.92) 70.47(39.41)
Transitional
period
62.76
(20.99)
73.69(21.30) 66.66(36.06) 64.37(33.02) 74.93(29.76) 76.37(28.90)
Long term
survivors
67.00
(18.65)
77.36(21.30) 76.97(32.54) 65.76(31.44) 71.92(28.83) 82.67(27.14)
P-value 0.478 0.400 0.034 0.461 0.574 0.179
Marital status
Single 68.11
(18.05)
73.91(23.69) 61.59(40.95) 59.78(39.22) 69.56(31.24) 66.66(41.43)
Married 65.56
(19.97)
77.83(17.98) 70.96(34.17) 63.95(32.00) 74.84(28.92) 81.04(25.86)
Divorced 58.33
(27.34)
62.85(29.31) 50.00(44.61) 55.95(38.31) 57.14(34.41) 70.23(37.65)
Widowed 56.04
(24.45)
67.50(28.08) 69.58(36.57) 66.04(35.37) 75.41(30.65) 71.79(35.28)
P-value 0.041 0.123 0.216 0.780 0.205 0.371
Educational
level
Illiterate 61.25
(24.29)
73.11(21.85) 67.77(33.59) 75.00(30.66) 78.24(28.74) 77.40(24.32)
Primary 54.16
(25.21)
60.66(27.14) 57.77(42.82) 54.72(32.65) 75.55(30.86) 77.22(30.47)
Intermediate 68.56
(23.13)
78.55(23.09) 64.39(42.81) 65.94(36.31) 71.73(33.87) 71.01(38.34)
High school 66.87
(17.12)
79.17(18.63) 73.04(33.18) 59.77(34.25) 71.19(29.46) 79.21(33.17)
College
graduate
65.27
(65.27)
76.34(76.34) 70.73(70.73) 58.33(58.33) 69.44(69.44) 77.38(77.38)
P -value 0.059 0.009 0.548 0.009 0.284 0.535
Employment
Yes 67.83
(15.88)
76.53(21.81) 73.00(36.24) 60.20(32.46) 72.00(29.82) 78.00(31.66)
No 62.47
(23.53)
73.51(21.89) 65.52(36.75) 64.00(33.58) 73.44(30.26) 74.48(30.68)
Retired 62.91
(18.58)
76.83(21.08) 74.12(32.58) 64.37(35.45) 74.16(29.46) 87.08(26.00)
P-value 0.428 0.516 0.196 0.559 0.924 0.024
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Table 3 Global health and functional scales in QLQ-C30 by independent variables (N = 239)a (Continued)
Monthly
income
<500 60.55
(23.06)
71.46(23.62) 63.61(36.96) 62.05(34.81) 72.39(30.22) 71.75(32.61)
500–999 67.10
(17.35)
78.59(18.88) 69.34(37.16) 65.02(32.54) 75.73(29.22) 79.82(30.00)
>1000 68.47
(19.79)
79.13(17.92) 82.60(27.65) 64.13(32.00) 72.82(30.70) 90.94(17.46)
P-value 0.036 0.087 0.005 0.974 0.818 0.001
Menopausal
status
Premenopause 67.20
(20.32)
76.84(20.34) 67.43(37.60) 59.49(34.30) 69.54(31.75) 74.24(33.45)
Perimenopause 67.82
(16.07)
77.77(20.15) 71.75(35.37) 62.96(33.65) 69.90(30.03) 83.79(28.86)
Postmenopause 57.77
(23.19)
70.88(23.51) 68.51(34.74) 67.97(32.41) 79.21(26.74) 78.65(26.58)
P-value 0.016 0.142 0.831 0.123 0.057 0.268
Pathological
staging
Stage 0 and I 66.87
(17.65)
74.33(22.26) 66.66(36.98) 59.58(31.72) 69.58(32.66) 82.08(28.59)
Stage II 65.55
(23.14)
74.55(23.43) 69.49(35.17) 64.58(32.92) 77.50(28.59) 72.31(30.88)
Stage III and IV 58. 08
(26.47)
68.23(23.60) 50.98(41.83) 53.67 (37.67) 67.15 (28.86) 65.68(34.55)
P-value 0.295 0.411 0.072 0.313 0.151 0.054
Metastases
Yes 52.45
(19.93)
55.29(24.69) 26.47(38.66) 42.64(37.71) 55.88(36.29) 57.29(37.00)
No 64.56
(21.25)
76.22(20.76) 71.81(33.79) 64.89(32.77) 74.61(29.03) 78.84(29.41)
P value 0.016 0.001 0.000 0.016 0.024 0.009
Mastectomy
Yes 60.47
(22.93)
71.86(22.81)777.57
(20.22)
64.22(37.31) 61.49(34.97) 74.64(28.91) 73.50(30.57)
No 66.87
(19.22)
72.74(34.43) 65.02(32.18) 71.89(30.94) 81.21(29.84)
P-value 0.026 0.053 0.053 0.536 0.613 0.010
Lumpectomy
Yes 67.08
(19.26)
77.68(20.36) 72.86(34.16) 65.48(31.92) 71.90(30.58) 81.40(29.59)
No 60.14
(22.88)
71.59(22.70) 63.86(37.59) 60.91(35.23) 74.70(29.26) 73.09(30.76)
P-value 0.017 0.033 0.048 0.435 0.514 0.007
Lymph node
dissection
Yes 63.44
(21.19)
75.50(21.28) 67.92(36.40) 62.64(33.70) 73.11(29.94) 77.47(30.50)
No 65.00
(22.75)
70.47(24.10) 70.95(34.61) 65.71(33.07) 73.33(30.30) 77.14(30.54)
P-value 0.771 0.255 0.753 0.545 0.937 0.776
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Predictors of quality of life
The predictors explained 24% of the variation in global
health (R-squared = 0.24). The predictors which had a
significant effect on global health given the other predic-
tors in the model were staging of the disease (P = 0.005)
and menopausal status (P = 0.031) (Table 5). The same
model was built for every domain in QLQ-C30. Metasta-
sis was a significant predictor in the physical and role
functioning models (P = 0.002 and 0.003) respectively.
Co-morbidities and chemotherapy were significant pre-
dictors in role functioning model (P = 0.032 and 0.009)
respectively.
Discussion
This is the first study to assess quality of life of breast
cancer survivors in Bahrain and indicates that Bahraini
women with breast cancer have average to good quality
of life functioning and low to average symptoms experi-
ence. Not surprisingly, the presence of metastases, ad-
vanced staging, having had a mastectomy as opposed to
lumpectomy and the shorter time elapsed since diagno-
sis had a major effect across all the domains of quality of
life of breast cancer survivors.
Comparison with previous literature
Our results were largely comparable to other Western
and Asian studies [13-15]. However, there are specific
domains that showed lower scores which could be re-
lated to socio-cultural and religious aspects.
The global health score obtained in this study from
Bahraini breast cancer survivors (63.9) is similar to that
obtained in other Western and Asian studies such as
South Korea (66.5), United Kingdom (66.8 and 69.8) and
Germany (65.5) [13-15]. This study was also similar to
other studies in Europe and Asia in showing that the
poorest functioning in terms of symptoms was for fa-
tigue followed by sleep disturbance, pain, hair loss and
arm symptoms [10,13-19].
Within this region, Bahraini women with breast cancer
have a lower quality of life than their counterparts in the
United Arab Emirates (74.6) but higher than Kuwait
(45.0) and Iran (32.0) [10,16,17]. However, caution has
to be used in comparing data from these studies as the
base populations vary in terms of age of participants,
time elapsed since diagnosis and the staging of disease.
It is of note that global quality of life amongst Bahraini
women was comparable with other studies despite the
limited psychological support for breast cancer survivors
in the Bahraini health care system. It may be that Bahraini
women receive psychological support through other
means such as the family or the wider society [20]. It could
also be that participants in this study had greater difficulty
understanding the meaning of quality of life and conse-
quently responded to questions more positively.
There is a substantial body of literature documenting
that comparison of quality of life data should go beyond
the usual presentation of observed mean scores [12,21].
Various approaches have been recommended but so far
there is no comprehensive approach suitable for the in-
terpretation of quality of life results from a global per-
spective. Some of the suggested approaches are: using
population-based reference values [12,22]; reporting the
minimum important difference (mostly a difference of
10 points or more was used to define a clinically relevant
change) [23]; and defining a particular proportion of pa-
tients achieving a predefined degree of benefit [23]. Al-
though these methods are meaningful, they are arbitrary
and subject to individual’s opinions. In this study we
used 10 points as the minimum important difference
and the proportion of patients achieving a particular de-
gree of benefit as two methods of interpreting our qual-
ity of life data. For example, although the mean score for
global QLQ – C30 indicated average to good function-
ing, only a third (38.5%) of participants met the 66.7%
criterion for good functioning. Using the same criteria,
poorer functioning for global quality of life was reported
Table 3 Global health and functional scales in QLQ-C30 by independent variables (N = 239)a (Continued)
Chemotherapy
Yes 64.41
(20.95)
76.00(20.73) 67.28(37.02) 61.31(34.19) 73.54(29.26) 77.16(30.70)
No 60.68
(22.88)
69.42(24.88) 73.55(31.73) 71.19(30.00) 72.10(32.78) 78.26(29.36)
P-value 0.358 0.122 0.472 0.080 0.828 0.895
Radiotherapy
Yes 64.25
(21.06)
75.82(21.94) 69.72(36.11 63.77(33.12) 73.40(29.60) 79.10(29.48)
No 60.74
(22.83)
68.94(19.68) 62.28(35.65) 60.58(36.25) 72.52(31.96) 68.42(33.73)
P-value 0.538 0.024 0.172 0.779 0.992 0.043
aP-value based on Kruskal Wallis or Mann Whitney tests.
bFor functional scales, higher scores indicate better functioning.
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Table 4 Functional and symptom scales in QLQ-BR23a
Functional scales in BR 23b Symptom scale in BR 23c
Characteristic Body
Image
Sexual
functioning
Sexual
enjoyment
Future
perspective
Systemic therapy
side effect
Breast
symptoms
Arm
symptoms
Upset by hair
loss
Age
≤50 year 72.53
(31.24)
29.25(29.88) 48.91(34.02) 55.55(39.69) 20.07(18.66) 16.35(19.75) 39.09(31.74) 51.41(43.47)
>50 years 79.88
(27.45)
21.38(29.16) 47.86(28.40) 68.97(37.78) 18.19(16.52) 10.06(14.87) 33.22(31.64) 39.02(41.43)
P-value 0.134 0.744 0.103 0.257 0.453 0.034 0.983 0.257
Time since
diagnosis
Early diagnosed 65.47
(37.33)
18.09(27.52) 55.55(35.76) 44.76(44.23) 25.85(19.77) 20.95(22.17) 43.80(32.44) 70.83(34.15)
Transitional
period
75.67
(30.32)
23.65(27.71) 44.44(27.89) 63.22(39.06) 17.83(17.28) 11.11(14.45) 32.18(29.57) 41.49(42.23)
Long term
survivors
80.33
(23.83)
33.33(32.76) 52.27(36.22) 65.77(35.92) 18.59(17.10) 14.55(20.50) 40.59(34.19) 41.90(44.53)
P-value 0.292 0.027 0.338 0.037 0.065 0.044 0.093 0.035
Marital status
Single 74.63
(34.31)
5.07(16.99) 66.66(−) 60.86(44.55) 25.05(25.32) 13.40(24.71) 35.26(29.89) 33.33(40.20)
Married 73.88
(29.97)
37.47(29.33) 48.83(32.03) 61.63(38.46) 16.96(14.81) 14.30(17.74) 38.22(31.81) 43.28(43.03)
Divorced 80.95
(27.62)
4.76(12.10) 0.00(−) 52.38(46.61) 30.95(20.09) 18.45(16.72) 35.71(31.17) 86.66(32.20)
Widowed 81.25
(27.59)
0.00 (0.00) - 63.33(38.34) 20.95(20.51) 9.58(15.04) 31.11(33.30) 43.33(38.65)
P-value 0.446 0.000 0.288 0.877 0.060 0.046 0.484 0.020
Educational level
Illiterate 82.32
(27.79)
24.71(31.87) 52.56(30.07) 75.00(33.96) 16.06(14.95) 9.72(15.65) 32.03(31.36) 28.07(40.46)
Primary 78.88
(25.49)
11.11(22.46) 33.33(30.86) 57.77(40.05) 21.11(17.58) 13.61(20.81) 43.70(34.39) 71.42(40.49)
Intermediate 71.01
(33.32)
28.98(32.26) 52.77(30.01) 63.76(44.84) 17.59(20.47) 16.30(16.94) 35.26(34.26) 75.00(38.83)
High school/
diploma
75.30
(30.46)
26.95(27.20) 44.20(34.46) 55.14(39.84) 20.92(18.87) 15.12(18.49) 36.35(30.73) 40.47(41.99)
College 67.26
(31.20)
34.52(31.96) 55.55(30.56) 54.76(38.83) 20.18(17.90) 15.07(18.88) 39.15(31.44) 55.07(42.17)
P -value 0.029 0.015 0.417 0.026 0.432 0.490 0.067 0.021
Employment
Yes 76.19
(28.31)
29.25(30.90) 53.33(34.69) 50.66(38.82) 20.47(19.76) 16.66(20.68) 38.00(30.12) 51.38(40.50)
No 75.57
(30.84)
24.94(29.14) 47.29(31.69) 63.69(38.93) 18.42(17.08) 13.47(18.10) 35.31(32.35) 42.30(43.34)
Retired 75.20
(28.77)
25.41(31.12) 47.05(31.31) 65.83(40.28) 20.83(17.80) 10.62(13.73) 39.44(32.11) 50.72(45.91)
P-value 0.885 0.697 0.756 0.070 0.683 0.425 0.610 0.558
Monthly income
<500 75.38
(30.40)
17.30(25.95) 42.85(30.42) 60.60(40.52) 21.51(17.70) 13.63(18.34) 35.35(30.44) 47.27(42.88)
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Table 4 Functional and symptom scales in QLQ-BR23a (Continued)
500–999 75.00
(29.37)
35.38(31.82) 50.00(35.30) 61.40(40.72) 17.62(20.91) 14.91(17.23) 37.42(33.89) 43.05(43.38)
>1000 78.62
(27.97)
78.62(30.19) 55.95(30.16) 63.76(35.01) 15.21(12.32) 10.86(16.18) 37.68 (32.32) 48.33(45.20)
P-value 0.780 0.000 0.231 0.965 0.035 0.354 0.901 0.906
Menopausal
status
Premenopause 71.43
(31.97)
30.00(29.93) 48.48(34.68) 56.36(39.29) 19.56(17.73) 17.27(20.05) 40.30(31.92) 48.97(43.08)
Perimenopause 77.31
(28.28)
26.85(29.08) 49.01(26.66) 56.48(41.26) 20.50(20.22) 15.74(19.08) 34.87(32.00) 54.76(46.42)
Postmenopause 80.20
(27.22)
20.45(29.33) 48.48(30.15) 69.25 (37.80) 18.408(16.88) 8.42(13.42) 32.71(31.31) 39.81(42.02)
P-value 0.091 0.049 0.985 0.047 0.876 0.001 0.169 0.473
Pathological
staging
Stage 0 and I 76.28
(28.26)
22.64(26.34) 43.75(33.81) 60.68(41.09) 19.65(13.69) 17.09(18.72) 42.16(32.16) 56.25(48.25)
Stage II 78.67
(29.57)
25.42(28.42) 47.31(33.08) 61.58(40.02) 20.33(19.24) 14.40(20.63) 36.34(31.21) 33.33(36.00)
Stage III and IV 61.51
(36.17)
20.09(25.87) 48.88(27.79) 52.94(45.03) 24.36(21.51) 15.93(19.82) 36.92(34.46) 50.00(40.82)
P-value 0.052 0.761 0.884 0.609 0.691 0.560 0.363 0.225
Metastases
Yes 71.56
(35.36)
14.70(24.21) 33.33(36.51) 47.05(39.19) 36.13(29.26) 28.43(25.52) 54.24(35.54) 43.33(44.58)
No 75.96
(29.46)
26.80(30.03) 49.39(31.84) 62.40(39.26) 17.95(15.91) 12.51(16.90) 35.21(31.12) 46.81(43.14)
P-value 0.585 0.117 0.299 0.131 0.013 0.008 0.033 0.831
Mastectomy
Yes 70.01
(33.22)
26.35(29.13) 47.77(32.10) 62.14(40.63) 19.69(19.06) 14.33(19.21) 37.75(31.66) 46.80(43.21)
No 81.26
(24.97)
25.49(30.52) 49.40(32.40) 60.45(38.22) 18.84(16.41) 12.99(16.89) 35.40(31.95) 46.15(43.36)
P-value 0.022 0.665 0.768 0.684 0.964 0.827 0.499 0.965
Lumpectomy
Yes 80.76
(24.91)
24.58(30.47) 48.80(33.61) 60.60(38.49) 18.80(16.26) 13.42(17.98) 35.44(31.76) 45.28(43.40)
No 70.24
(33.58)
27.33(29.09) 48.33(30.94) 60.02(40.43) 19.75(19.26) 13.98(18.22) 37.77(31.86) 47.82(43.12)
P-value 0.059 0.322 0.933 0.736 0.931 0.846 0.529 0.788
Lymph node
dissection
Yes 74.53
(30.39)
25.75(29.59) 47.81(33.38) 59.50(39.52) 19.59(17.60) 13.12(17.15) 37.22(31.87) 48.23(43.18)
No 81.42
(26.66)
25.71(30.87) 52.08(24.24) 70.47(37.72) 17.50(19.07) 15.71(22.11) 32.06(31.28) 38.46(42.70)
P-value 0.249 0.884 0.754 0.115 0.406 0.728 0.348 0.434
Chemotherapy
Yes 73.89
(30.73)
27.03(29.70) 48.14(33.40) 60.17(39.97) 20.10(18.26) 14.29(18.49) 37.95(31.22) 46.89(42.58)
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in Kuwait (10.9% scored ≥ 66.7 on the same scale) [17].
Problematic functioning for global quality of life in a
Korean study was reported by 21.5% of participants [13],
in Kuwait by 6.2% [17] and in our study by only 5.4%.
This analysis is not available in many studies so com-
parison is not always possible. One should be cautious
interpreting this finding because, while the sample in our
study was chosen at random from a national cancer regis-
try, the Korean study was hospital based and the Kuwaiti
authors used a convenience sample. Another factor to
mention is the higher mean age of our participants (50.2)
compared to both studies (Range 46.6- 48.3).
Similar to many other studies [24,25], women showed
an average performance on most functional scales except
for sexual functioning and enjoyment which demon-
strated poor functioning. Reasons suggested for dis-
turbed sexual function include low self esteem, hair loss,
abrupt menopause, vaginal dryness, partner's difficulty
understanding one’s feelings and body image problems
[24,25]. However, one should note that in our study
most unmarried subjects did not respond to the ques-
tion on sexual functioning as they may deem it culturally
improper to express sexual desires or affairs “And say to
the believing women that they should lower their gaze
and guard their modesty; that they should not display
their beauty and ornaments except what (must ordinar-
ily) appear thereof”(Sorat Al Noor 24:31, The Holy
Quran). A similar argument was made in a Moroccan
study that clearly described sexual impact in breast can-
cer as a taboo in the clinical setting [26].
Factors associated with quality of life scores
The lack of an association between age and quality of life
as opposed to most [15,18] but not all [19] previous
studies could be due to several factors. First, different
age groupings were used in the various studies. Second,
the questionnaire does not contain questions about spe-
cific concerns related to younger women such as fertility
and abrupt menopause [15,24], thereby reducing the im-
pact of these issues on quality of life of younger women.
Interestingly, single women had better global quality
of life, whereas married women had better physical func-
tioning which is in agreement with some but not all
studies [27,28]. One of the reasons may be related to the
fact that single women are under less pressure to worry
about their partner’s opinion because traditionally and
religiously the local Islamic society places constraints
around dating and premarital sex “Nor come nigh to
adultery: for it is a shameful (deed) and an evil, opening
the road (to other evils”(Sorat Al Israa 17:32, The Holy
Quran). On the other hand, polgyny is still allowed in
some Islamic countries including Bahrain, with the spe-
cific limitation that a man can have up to four wives at
any one time “Marry women of your choice, Two or three
or four; but if you fear that you shall not be able to deal
justly (with them), then only one” (Sorat Al Nissa 4:3,
The Holy Quran). This may be intimidating to some
married women who fear that a serious and crippling ill-
ness could be an excuse for their husband to take a sec-
ond wife, especially if the woman was unable to attend
to her husband’s needs . Married women, however, func-
tioned better physically as they had to continue to do
the house work regardless of the disease [29].
Breast conservative surgery (lumpectomy) was not
only associated with better global quality of life but also
with better physical, role and social functioning as in
previous studies [19,30]. Together with recent data
about comparable survival time for both procedures in
early stage breast cancer [31], this should have an impli-
cation on surgeon’s and patient’s choice of surgery. How-
ever, receiving chemotherapy, radiotherapy or hormone
therapy was not associated with significant deterioration
of quality of life. A significant amount of literature has
shown that the impairment in quality of life due to such
therapy is minor and limited to short term rather than
long term quality of life [32,33].
Long term survivors showed better role functioning,
sexual functioning and future perspectives compared to
early survivors. On the other hand, early survivors
reported more breast symptoms and were more upset by
Table 4 Functional and symptom scales in QLQ-BR23a (Continued)
No 82.78
(25.05)
21.37(29.95) 50.98(23.91) 65.94(36.84) 15.76(15.15) 11.05(16.10) 30.91(33.69) 43.58(47.88)
P-value 0.071 0.161 0.781 0.387 0.144 0.213 0.097 0.806
Radiotherapy
Yes 76.56
(29.28)
26.14(30.12) 50.34(31.83) 61.11(39.27) 18.37(16.86) 13.25(17.79) 36.64(31.58) 43.20(42.30)
No 70.72
(32.78)
24.77(28.22) 38.88(32.83) 62.28(40.39) 24.06(21.58) 15.78(19.54) 36.25(33.15) 61.11(44.64)
P-value 0.335 0.970 0.193 0.837 0.220 0.389 0.869 0.117
aP-value based on Kruskal Wallis or Mann Whitney tests.
bFor functional scales, higher scores indicate better functioning.
cFor symptom scales, higher scores indicate worse functioning.
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Table 5 Final linear regression model with parameter estimates for QLQ functional scales
Global QoL score Physical functioning Role functioning Emotional functioning Cognitive functioning Social functioning
Variable Standardized
Coefficients
Beta
Significance Standardized
Coefficients
Beta
Significance Standardized
Coefficients
Beta
Significance Standardized
Coefficients
Beta
Significance Standardized
Coefficients
Beta
Significance Standardized
Coefficients
Beta
Significance
Constant 63.298 <0.001 36.082 0.024 56 0.032 77.93 0.001 71.909 0.001 41.898 0.047
Age > 50 −0.007 0.956 0.187 0.103 0.022 0.848 2.757 0.007 0.135 0.285 0 0.999
No = 0
Yes = 1
Married 0.116 0.231 0.129 0.168 0.076 0.434 0.837 0.404 0.11 0.288 0.35 <0.001
No = 0
Yes = 1
Education −0.024 0.844 0.192 0.103 −0.021 0.861 −0.25 0.803 −0.112 0.384 −0.137 0.244
No = 0
Yes = 1
Employment −0.018 0.853 −0.109 0.252 −0.078 0.429 −0.863 0.39 0.036 0.732 −0.054 0.571
No = 0
Yes = 1
High Income 0.109 0.29 0.086 0.391 0.171 0.098 1.612 0.11 0.101 0.361 0.25 0.014
No = 0
Yes = 1
Menopause −0.259 0.031 −0.128 0.269 0.068 0.565 −0.621 0.536 −0.01 0.934 0.034 0.769
No = 0
Yes = 1
Advanced
stage
−0.275 0.005 −0.061 0.516 −0.189 0.051 −0.54 0.59 −0.106 0.304 −0.156 0.101
No = 0
Yes = 1
Late survivors −0.105 0.263 −0.021 0.819 0.071 0.447 0.861 0.391 −0.067 0.506 −0.015 0.873
No = 0
Yes = 1
Comorbidities −0.027 0.783 −0.046 0.63 0.054 0.58 −2.171 0.032 0.037 0.725 −0.088 0.363
No = 0
Yes = 1
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Table 5 Final linear regression model with parameter estimates for QLQ functional scales (Continued)
Metastases −0.086 0.385 −0.297 0.002 −0.303 0.003 −1.691 0.094 −0.174 0.1 −0.103 0.285
No = 0
Yes = 1
Lumpectomy 0.321 0.205 0.45 0.068 0.15 0.551 0.746 0.457 0.072 0.789 0.265 0.282
No = 0
Yes = 1
Mastectomy 0.319 0.203 0.417 0.087 0.109 0.659 0.938 0.35 0.128 0.632 0.166 0.495
No = 0
Yes = 1
Lymph node
dissection
−0.068 0.461 0.052 0.559 −0.01 0.917 −1.763 0.081 −0.013 0.892 0.031 0.731
No = 0
Yes = 1
Chemotherapy −0.033 0.743 −0.07 0.466 −0.061 0.535 −2.646 0.009 −0.095 0.371 −0.043 0.654
No = 0
Yes = 1
Radiotherapy −0.085 0.376 0.159 0.089 0.061 0.524 0.139 0.89 −0.046 0.65 0.083 0.377
No = 0
Yes = 1
Hormonal
therapy
0.036 0.688 −0.063 0.464 −0.178 0.047 −0.76 0.449 0.04 0.677 0.008 0.931
No = 0
Yes = 1
R squared 0.24 0.28 0.25 0.25 0.132 0.281
P-value 0.015 0.002 0.009 0.01 0.455 0.002
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their hair loss. This is expected as the first year is usually
the year during which patients receive adjuvant therapy
and suffer from its various complications. This is in line
with many previous studies which showed that the lon-
ger time since diagnosis is, the better the quality of life
will be [18,34-36]. One should note that this study did
not compare quality of life of the same individuals at
several time intervals but compared different subjects
with various time elapsed since diagnosis.
The current study provided important information
about Bahraini breast cancer survivors with several
strengths including randomized sampling method, use of
standardized measures of quality of life, a satisfactory re-
sponse rate of 71%, and the use of a clinically meaning-
ful analysis. However, it has limitations that should be
addressed in future research including lack of a disease-
free control group and incomplete clinical information
about cancer in the Cancer Registry especially with re-
spect to grade and stage of the disease.
Implications for practice and policy
The results are important when counseling patients about
side effects of the disease and the need for greater atten-
tion to cancer related symptoms such as fatigue, pain, in-
somnia, arm symptoms and hair loss. Furthermore, sexual
issues after breast cancer diagnosis and treatment should
be addressed and explored in a culturally sensitive way.
Due to improved quality of life and comparable survival
time, lumpectomy should be considered in all women with
early stage disease. Special care and attention should be
given to women with metastatic lesions as their quality of
life is markedly affected in most quality of life domains.
Further research should address cultural differences in is-
sues related to sexuality, body image and interpretation of
quality of life as a concept.
Conclusion
Bahraini breast cancer survivors reported favorable overall
global quality of life. Bahraini women showed good func-
tioning on most QLQ-C30 functional scales, with the
lowest score for emotional functioning. Fatigue, sleep dis-
turbance and pain were the most bothersome symptoms.
In the disease specific tool, women reported the lowest
performance in sexual enjoyment and functioning whereas
arm symptoms and hair loss were among the most severe
symptoms reported. Many factors were related to lower
global quality of life including marital status, menopausal
status, metastases, monthly income and type of surgery
performed. Predictors of global health quality of life were
staging of the disease and menopausal status whereas me-
tastases predicted physical and role functioning. This
study highlights the women at risk of poorer quality of life
after breast cancer and the issues that most need to be
addressed in this Middle East society.
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